Subscribe

Can-Fite BioPharma Ltd. (CANF.TA)

ILA493.10 -31.80 (-6.06%)
IL TLV Healthcare Biotechnology
Address 10 Bareket Street 4951778
Petah Tikva, IL
CEO Pnina Fishman
Website canfite.com
IPO 2005-10-06
ISIN IL0010944739

Explore sections of this company profile

Also trades on New York Stock Exchange American · CANF (USD) Tel Aviv Stock Exchange · CANF.TA (ILA)
Description

Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
ILA493.10 -31.80 (-6.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
23.8K
Beta
0.01
Float Shares
5.12B
Free Float %
100.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.19% -3.41% -8.58% -34.86% -84.40% -84.40% -88.86% -94.97% -99.33% -99.97% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (1 ratings, all time) Buy
Price Targets & DCF
Current price
493.10
Ratings Trend (MoM) 100% Bullish
Rating 2026-02 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
1,271.27
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -35.0% Q2'25: -36.1% (vs Q2'24)
  • ✗
    EPS growth Biotechnology: +29.7%
    -179,344.4% Q2'25: +36.4% (vs Q2'24)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -2,347.9% Q2'25: -2,353.0% (vs Q2'24)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -2,456.8% Q2'25: -2,424.8% (vs Q2'24)
  • ✓
    ROIC Biotechnology: -16.1%
    — Q2'25: +340.5% (vs Q2'24)
  • ✓
    Share dilution Biotechnology: -3.4%
    -99.9% ★ Q2'25: +87.3% (vs Q2'24)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.01× Q2'25: -0.01× (vs Q2'24)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.03) × ERP
WACC = 97% × Ke + 3% × Kd (21.3%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 493.10
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
164.7K
est: 137.4K (+19.9%)
169.5K
est: 399.6K (-57.6%)
844.7K
est: 863.5K (-2.2%)
3.82M
est: 3.76M (+1.5%)
2.03M
est: 1.72M (+17.9%)
763.0K
est: 748.8K (+1.9%)
853.0K
est: 835.8K (+2.1%)
810.0K
est: 1.24M (-34.6%)
743.0K
est: 698.0K (+6.5%)
674.0K
est: 1.00M (-32.6%)
438.4K
est: 202.0K (+117.0%)
20.71M
20.71M – 20.71M
+10,152.3% YoY
2.54M
2.54M – 2.54M
-87.7% YoY
27.98M
27.98M – 27.98M
+1,001.5% YoY
61.83M
61.83M – 61.83M
+120.9% YoY
87.87M
87.87M – 87.87M
+42.1% YoY
EBITDA
-6.40M
est: -137.4K (-4,556.9%)
-8.68M
est: -399.6K (-2,071.4%)
-7.17M
est: -863.5K (-729.9%)
-6.13M
est: -3.76M (-62.8%)
-11.99M
est: -1.72M (-596.0%)
-14.13M
est: -748.8K (-1,786.6%)
-12.83M
est: -835.8K (-1,434.8%)
-10.08M
est: -1.24M (-714.4%)
-8.18M
est: -698.0K (-1,072.0%)
-8.12M
est: -1.00M (-712.3%)
-10.74M
est: -202.0K (-5,219.1%)
-20.71M
-20.71M – -20.71M
-10,152.3% YoY
-2.54M
-2.54M – -2.54M
+87.7% YoY
-27.98M
-27.98M – -27.98M
-1,001.5% YoY
-61.83M
-61.83M – -61.83M
-120.9% YoY
-87.87M
-87.87M – -87.87M
-42.1% YoY
EBIT
-6.42M
est: -137.4K (-4,568.8%)
-8.36M
est: -399.6K (-1,993.1%)
-6.40M
est: -863.5K (-641.6%)
-6.14M
est: -3.76M (-63.2%)
-12.01M
est: -1.72M (-596.8%)
-14.14M
est: -748.8K (-1,788.2%)
-12.84M
est: -835.8K (-1,436.4%)
-10.10M
est: -1.24M (-715.5%)
-8.20M
est: -698.0K (-1,074.1%)
-8.13M
est: -1.00M (-713.0%)
-10.77M
est: -202.0K (-5,232.0%)
-20.71M
-20.71M – -20.71M
-10,152.3% YoY
-2.54M
-2.54M – -2.54M
+87.7% YoY
-27.98M
-27.98M – -27.98M
-1,001.5% YoY
-61.83M
-61.83M – -61.83M
-120.9% YoY
-87.87M
-87.87M – -87.87M
-42.1% YoY
Net Income
-4.80M
est: -303.30M (+98.4%)
-6.90M
est: -336.94M (+98.0%)
-4.97M
est: -214.12M (+97.7%)
-6.57M
est: -279.45M (+97.6%)
-12.63M
est: -1.33B (+99.1%)
-14.44M
est: -66.53M (+78.3%)
-12.60M
est: -40.01M (+68.5%)
-10.17M
est: -25.84M (+60.6%)
-7.63M
est: -9.80M (+22.1%)
-7.88M
est: -20.08M (+60.8%)
-10.64M
est: -428.4K (-2,383.1%)
-773.9K
-773.9K – -773.9K
-80.6% YoY
-193.5K
-193.5K – -193.5K
+75.0% YoY
67.0K
67.0K – 67.0K
+134.6% YoY
245.6K
245.6K – 245.6K
+266.7% YoY
372.1K
372.1K – 372.1K
+51.5% YoY
SGA
2.70M
est: 570.3K (+373.4%)
2.70M
est: 1.66M (+62.6%)
2.95M
est: 3.58M (-17.7%)
3.16M
est: 15.62M (-79.8%)
3.06M
est: 7.15M (-57.2%)
2.95M
est: 3.11M (-5.1%)
3.85M
est: 3.47M (+10.8%)
3.14M
est: 5.14M (-38.8%)
2.96M
est: 2.90M (+2.0%)
3.05M
est: 5.17M (-41.1%)
3.94M
est: 1.05M (+276.8%)
107.15M
107.15M – 107.15M
+10,152.3% YoY
13.14M
13.14M – 13.14M
-87.7% YoY
144.78M
144.78M – 144.78M
+1,001.5% YoY
319.88M
319.88M – 319.88M
+120.9% YoY
454.61M
454.61M – 454.61M
+42.1% YoY
EPS
-0.27
est: -0.14 (-93.7%)
-0.30
est: -0.15 (-93.7%)
-0.19
est: -0.10 (-93.1%)
-0.17
est: -0.13 (-32.4%)
-0.15
est: -0.61 (+75.5%)
-0.04
est: -0.03 (-38.4%)
-0.03
est: -0.02 (-63.1%)
-0.01
est: -0.01 (-5.3%)
-0.01
est: 0.00 (-33.2%)
0.00
est: -12.19 (+100.0%)
-6.46
est: -0.26 (-2,384.6%)
-0.47
-0.47 – -0.47
-80.6% YoY
-0.12
-0.12 – -0.12
+75.0% YoY
0.04
0.04 – 0.04
+134.6% YoY
0.15
0.15 – 0.15
+266.7% YoY
0.23
0.23 – 0.23
+51.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-28 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-27 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-26 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-25 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-20 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-19 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-18 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-15 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-14 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-13 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-12 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-11 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-08 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-07 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-06 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-05 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-04 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-01 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-30 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-29 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-28 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-27 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-8.37M
OE per share TTM
0.00
Owner's Yield
-108.53%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
13.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-21.5K
Shares Outstanding
5.12B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Motti Farbstein Chief Executive Officer & Chief Operating and Financial Officer 616.0K male
Pnina Fishman Founder, Chief Scientific Officer & Executive Chairperson 516.0K —
Sari Fishman Vice President of Business Development 368.0K —
Stephen A. Harrison FACP Member of Clinical Advisory Board & Consulting Chief Medical Officer — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology